<DOC>
	<DOCNO>NCT02109445</DOCNO>
	<brief_summary>This study consist Phase 1b portion aim determine maximum tolerate dose safety profile PF-03084014 combination gemcitabine nab-paclitaxel follow Phase 2 portion evaluate efficacy triple combination term overall survival patient metastatic pancreatic ductal adenocarcinoma previously treat anticancer therapy .</brief_summary>
	<brief_title>Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically cytologically diagnosis metastatic ductal adenocarcinoma pancreas . No prior radiotherapy , surgery chemotherapy investigational therapy metastatic disease . Prior adjuvant therapy 5FU gemcitabine ( Â± gemcitabine post radiation ) administer radiosensitizer allow , provide least 6 month elapse last dose study registration Tumor tissue available ( Archival 6 month old de novo biopsy ) Measurable disease per RECIST 1.1 Performance Status ( ECOG ) 0 1 Symptomatic brain metastasis require steroid Prior therapy gamma secretase inhibitor Notch pathway inhibitor Major surgery within 4 week registration current study Known hypersensitivity gemcitabine nabpaclitaxel excipients Current anticipate need food drug strong/moderate CYP3A4 inhibitor inducer Diagnosis second malignancy within 3 year prior registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>